Clinical Trial of GP (GEM+DDP) Sequential Therapy versus Concurrent Chemoradiotherapy for Localized Advanced Non-small Cell Lung Cancer
- VernacularTitle:吉西他滨联合顺铂序贯与同期放化疗治疗局部晚期非小细胞肺癌临床比较
- Author:
Fangyang LU
;
Guijia HUANG
;
Lili ZHAO
;
Faqiang MA
- Publication Type:Journal Article
- Keywords:
Non-small cell lung cancer;
Drug therapy;
Radiotherapy;
Gemcitabine
- From:
China Pharmacy
2005;0(20):-
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE: To evaluate the efficacy and toxicity of the sequential chemoradiotherapy of GP(GEM+DDP) versus concurrent chemoradiotherapy for localized Non-small cell lung cancer(NSCLC).METHODS: 64 patients with stage Ⅲa and Ⅲb NSCLC were divided into two groups: Sequential group were treated with gemcitabine(1 250 mg?m-2,on d1 and d8),cisplatin(30 mg?m-2 on d1～d3) followed radiotherapy;synchronous group were treated with gemcitabine(1 000 mg?m-2,on d1 and d8),cisplatin(20 mg?m-2 on d1～d3) plus concurrent radiotherapy.RESULTS: There was no difference in short-term efficacy and toxicity between the two groups but significant difference was noted in long-term effect.CONCLUSION: There were no difference between GP sequential treatment and concurrent chemoradiotherapy for localized NSCLC in short-term effect and toxicity,but synchronous group was better than sequential group in long-term effect.
